Valneva’s IXCHIQ® Vaccine Expands Access to Adolescents in Europe

Valneva SE  has reached a major milestone with the European Commission's approval of its chikungunya vaccine, IXCHIQ®, for adolescents aged 12 and older. This approval follows its previous authorization for adults in July 2024, further strengthening efforts to combat this mosquito-borne virus. With this label extension, the single-dose vaccine is now accessible to adolescents across the EU, Norway, Liechtenstein, and Iceland, offering broader protection against a disease that has long lacked a preventive solution.

IXCHIQ® is the first and only licensed chikungunya vaccine worldwide, marking a breakthrough in global health. Already approved for adults in the U.S., Canada, and the U.K., Valneva is actively seeking similar approvals for adolescents in these regions. With this expanded access, families and healthcare providers now have a powerful tool to safeguard younger populations against chikungunya’s debilitating effects, reinforcing Valneva’s commitment to innovative vaccine solutions.